Jabil Expands Pharmaceutical Manufacturing With Pharmaceuticals International Acquisition
Jabil acquires Pii to expand its pharmaceutical manufacturing and drug development expertise.
Breaking News
Feb 05, 2025
Simantini Singh Deo

Jabil Inc., a global leader in engineering and manufacturing, has officially completed its acquisition of Pharmaceutics International, Inc. (PII) as of February 3, 2025. Pii, a specialized contract development and manufacturing organization (CDMO), brings expertise in aseptic filling, lyophilisation, and oral solid dose manufacturing, key areas in early-stage, clinical, and commercial drug production.
Mike Mahaz, SVP of Global Business Units, Healthcare, at Jabil, commented, “As the pace of healthcare innovation accelerates, pharmaceutical companies need partners who can help them scale rapidly with a focus on quality and safety. Jabil and Pii’s combined capabilities can provide end-to-end support for pharmaceutical customers, offering one safe, trusted pair of hands to simplify their entire supply chain.”
On behalf of our board and fellow shareholders at Athyrium Capital Management, Hildred Capital, and Pharmascience Inc., I want to thank our management and staff for their splendid work building the company over the past several years. Jabil is the perfect owner to continue the momentum of the business. With their resources and capabilities, we believe our customers and employees will be well served going forward,” said James Gale, Chairman of Pii and managing director of Signet Healthcare Partners.
This acquisition strengthens Jabil’s Pharmaceutical Solutions portfolio, which includes drug delivery devices like auto-injectors, inhalers, and on-body pumps. With Pii’s advanced manufacturing capabilities and deep scientific expertise, Jabil is now well-positioned to meet the growing demand for clinical and commercial drug manufacturing, particularly in high-growth markets like GLP-1 therapies.
“Jabil is very pleased to announce this acquisition. With our shared commitment to creating the best solutions for patients worldwide, we believe that adding Pii’s capabilities, supported by over 300 team members, is a perfect fit for Jabil and our customers. The convergence of Jabil’s and Pii’s complementary capabilities will bolster Jabil's customer offering and support business growth potential as we enter the CDMO market,” said James O’Gorman, Vice President of Pharmaceutical Solutions at Jabil.
John Fowler, President and CEO at Pii, said, “This acquisition marks an exciting new chapter for Pii. We look forward to leveraging Jabil’s extensive expertise to accelerate our mission of delivering best-in-class drug development and manufacturing solutions to our customers and, ultimately, the patients we serve.”
Pharmaceuticals International Inc., founded in 1994, operates from a 360,000-square-foot campus in Hunt Valley, Maryland, featuring over 70 GMP-compliant manufacturing rooms, containment suites for high-potency compounds, an aseptic facility for injectables, and state-of-the-art labs for formulation development, analytics, and microbiology. By joining Jabil, Pii will benefit from expanded global reach, advanced automation, and enhanced supply chain efficiencies, helping accelerate pharmaceutical innovation.